Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 4 people enrolled
- Started
- 22 Feb 2024
- Ended
- 4 Mar 2025
- Type of study
- Interventional
- Treatments tested
- 166Holmium microspheres (QuiremSpheres®)
- Record updated
- 19 September 2025
- Why it stopped
- Terumo Europe NV permanently discontinued production of Holmium platform SIRT product range
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Provided written informed consent
- Female or male aged 18 years and over
- Diagnosis of HCC established according to AASLD criteria: nodule >1 cm in a patient at risk for HCC, with combination of arterial hypervascularity and venous or delayed phase wash-out on multiphase CT-scan or MRI-scan. LR-5 and LR- 4 based on Liver Imaging Reporting and Data System can be included
- No curative treatment options (resection, transplant, or in case of solitary tumour, RFA)
- Life expectancy of at least 6 months
- ECOG Performance status 0-1
- Liver-dominant disease (maximum 5 lung nodules all ≤1.0 cm, solitary clinically stable adrenal metastasis, and mesenteric or portal lymph nodes all ≤2.0 cm are accepted)
- Child-Pugh class A5-6 or B7
- At least one measurable liver lesion according to the modified RECIST criteria
- Negative pregnancy test for women of childbearing potential. Female patients of childbearing potential should use a highly effective acceptable method of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation) or should be more than 1 year postmenopausal or surgically sterile during their participation in this study (from the time they sign the consent form), to prevent pregnancy
Who cannot take part
- Hepatic radiation therapy within the last 4 weeks before the start of study therapy
- Previous or current treatment with RE. Previous treatment with TACE, surgery, RFA, and previous or current treatment with systemic treatment are allowed
- Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy
- Significant cardiac event (e.g., myocardial infarction, superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease ≥2) within 3 months before entry, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia
- Previous enrolment in the present study
- Evidence of significant extrahepatic disease (MRI-scan liver and multiphase abdominal CT as well as a thoracic CT are routinely performed at screening)
- Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression
- Evidence of untreated, clinically significant grade 3 portal hypertension (i.e. large varices at oesophagi-gastro-duodenoscopy). In these cases, therapy with non-selective beta-blocker (propranolol) or rubber band ligation should be instituted according to accepted guidelines. In case of small varices, prophylactic propranolol is advised
- Portal vein thrombosis (tumour and/or bland) of the main branch (diagnosed on contrast enhanced transaxial images). Involvement of the right or left portal vein branches and more distal is accepted
- Untreated active hepatitis. In case of detectable viral HBV load, appropriate treatment should be instituted
- Severe allergy for intravenous contrast used (Visipaque®)
- Serum bilirubin > 34 umol/L in the absence of a reversible cause
- Non-correctable INR >1.5 in case of femoral approach (as opposed to radial)
- Platelet count <50 109/l
- Glomerular filtration rate <35 ml/min
- Pregnancy or breastfeeding
- Patients who are declared incapacitated
- Male patients who are not surgically sterile or do not use an acceptable method of contraception during their participation in this study (from the time they sign the consent form), to prevent pregnancy in a partner
- Transjugular intrahepatic portosystemic shunt (TIPS)
- Body weight over 150 kg (because of maximum table load)
- Lung shunt >30 Gy, as calculated using scout dose SPECT/CT
- Extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to test the safety and effectiveness of a medical device called 166-Holmium microspheres (QuiremSpheres®) in patients with hepatocellular carcinoma (HCC) . The main questions it aims to answer are:
Read full original descriptionShow less
* What is the safety and toxicity profile of the 166-Holmium microspheres? * Is the device effective in treating HCC?
Participants will undergo a range of screening procedures to confirm they are eligible and to record their baseline results, including:
* A Computed Tomography (CT) scan * A Magnetic Resonance Imaging (MRI) scan * Blood tests * Quality of life questionnaires
Before receiving treatment with QuiremSpheres® the participant will receive a 'scout' dose of the microspheres, to check whether there is distribution of the radioactivity to other non-target areas of the body. This is measured using Single-Photon Emission Computed Tomography-CT imaging. If the distribution to non-target areas is deemed to not be too high, the participant will go on to receive the individualised therapeutic dose of QuiremSpheres®. Follow-up visits will occur 3 and 6 weeks post-treatment dose, and then at 3 and 6 months.
The group in the trial
- Radioembolisation with 166Holmium microspheresTreatment being tested
Treatment: 166Holmium microspheres (QuiremSpheres®)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma; a Multi-centre, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study
- Publications
- Record updated
- 19 September 2025